Antimicrobial Use Guidelines (AMUG) version 21 - UW Health

38. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin inpatients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25:433-437.39. Moellering RC, Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother. 1984;14 SupplD:43-52.40. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations usingseven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm.2006;63:2365-2370.41. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of diseaseand pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755-773.42. Spinler SA, Nawarskas JJ, Boyce EG, Connors JE, Charland SL, Goldfarb S. Predictiveperformance of ten equations for estimating creatinine clearance in cardiac patients. IohexolCooperative Study Group. Ann Pharmacother. 1998;32:1275-1283.43. Yang RH, Rong XZ, Hua R, Zhang T. Pharmacokinectics of vancomycin and amikacin in thesubeschar tissue fluid in patients with severe burn. Burns. 2009;35:75-79.44. Nakayama H, Echizen H, Tanaka M, Sato M, Orii T. Reduced vancomycin clearance despiteunchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.Ther Drug Monit. 2008;30:103-107.45. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics ofvancomycin when administered during high flux hemodialysis. Clin Nephrol. 1998;50:51-55.46. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosingregimen in patients receiving high-flux hemodialysis. Am J Kidney Dis. 2005;46:681-687.47. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130courses of therapy. Kidney Int. 1996;50:929-936.48. Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am JHealth Syst Pharm. 2004;61:1812-1816.49. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adultpatients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159-1166.Additional helpful references50. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era ofincreasing doses. Antimicrob Agents Chemother 2009;53:483-6.51. Nakayama H, Echizen H, Tanaka M, Sato M, Orii T. Reduced vancomycin clearance despiteunchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.Ther Drug Monit 2008;30:103-7.52. Pea F, Furlanut M, Negri C, Pavan F, Crapis M, Cristini F, Viale P. Prospectively validateddosing nomograms for maximizing the pharmacodynamics of vancomycin administered bycontinuous infusion in critically ill patients. Antimicrob Agents Chemother 2009;53:1863-1867.